Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27479914 | 1.00 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29715788 | 1.00 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL27835408 | 0.82 | CA2 (0.42) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL31161149 | 0.82 | CA2 (0.43) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL9374719 | 0.81 | SIGMAR1 (0.44) | SIGMAR1ADRA2ACHRM2CHRM4CHRM5 | |
| SCHEMBL1820344 | 0.81 | CA2 (0.41) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL13528608 | 0.81 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6493103 | 0.78 | GABRA1 (0.47) | CA2SSTR4CHRM4 | |
| SCHEMBL9290880 | 0.77 | SSTR4 (0.45) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6747489 | 0.77 | CA2 (0.44) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240167066-A1 | METHOD FOR PRODUCING DEMETHYLATED COMPOUND | DAICEL CORPORATION (JP) | 2024-05-23 | — | — | US | disclosed |
| WO-2022202961-A1 | METHOD FOR PRODUCING DEMETHYLATED COMPOUND | 株式会社ダイセル | 2022-09-29 | — | — | WO | disclosed |
| EP-3353147-B1 | SYNTHESIS OF TERPHENYL COMPOUNDS | VECTUS BIOSYSTEMS LTD (AU) | 2021-01-13 | — | — | EP | disclosed |
| CN-112041296-A | Aminoacetamides containing benzo-oxy-alicyclic structure and use thereof | 上海璃道医药科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-9561272-B2 | Compositions and methods for modulating immune responses | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-02-07 | — | — | US | disclosed |
| CN-102186835-B | Process for preparing nebivolol | ZACH SYSTEM S.P.A. (IT) | 2016-01-13 | — | — | CN | disclosed |
| CN-102471325-B | Process for preparing nebivolol | ZACH SYSTEM S.P.A. (IT) | 2015-09-09 | — | — | CN | disclosed |
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150202285-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-07-23 | — | — | US | disclosed |
| US-9017697-B2 | Compositions and methods for modulating immune responses | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-04-28 | — | — | US | disclosed |
| EP-0579412-B1 | 1,2,4-trioxygenated benzene derivatives useful as a leukotriene antagonists | LILLY CO ELI (US) | 1998-10-07 | — | — | EP | disclosed |
| US-5352690-A | For asthma, allergies | ELI LILLY AND COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
| EP-0579412-A1 | 1,2,4-trioxygenated benzene derivatives useful as a leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1994-01-19 | — | — | EP | disclosed |
| CN-1019393-B | Substituted N-[(4-piperidingl] alkyl] bicyclic condensed oxazol and thiazolaminer | JANSSEN PHARMACEUTICA NV (BE) | 1992-12-09 | — | — | CN | disclosed |
| US-4824971-A | 2-allylchromans | HOFFMAN-LA ROCHE INC. (US) | 1989-04-25 | — | — | US | disclosed |
| EP-0235510-B1 | 3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2H-1-BENZOPYRAN DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-03-08 | — | — | EP | disclosed |
| US-4806661-A | Chromanemelonate esters | HOFFMANN-LA ROCHE INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4752646-A | 2-halochromans | HOFFMANN-LA ROCHE INC. (US) | 1988-06-21 | — | — | US | disclosed |
| EP-0235510-A2 | 3,4-Dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran derivatives and processes for their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-09 | — | — | EP | disclosed |
| CN-86102349-A | Preparation N-[(4-piperidyl) alkyl] the bicyclic condensed azoles that replaces and the method for thiazole amine | — | 1986-11-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | HLA-DRB1, CD74, CHI3L1 | CA2 2982/4885HTR1A 4558/4885SIGMAR1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.